Physician profile
Michael Y Sy
NPI 1376835629
$91,001.50
in general payments reported to CMS, 2019-2025
16 companies · $69K in 2025
The $69K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.15 · 2021: $3,904 · 2022: $595 · 2023: $9,499 · 2024: $7,834 · 2025: $69K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Consulting Fee: $34K · Travel and Lodging: $5,134 · Food and Beverage: $4,286 · Education: $60.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,460.00 |
| Consulting Fee | $33,523.00 |
| Travel and Lodging | $5,134.37 |
| Food and Beverage | $4,285.73 |
| Education | $60.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $46,899.92 | 2022-2025 | Ultomiris, Soliris |
| Genentech USA, INC. | $13,794.96 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Astrazeneca Pharmaceuticals Lp | $9,945.87 | 2023-2024 | Evusheld, Flumist Quadrivalent |
| Amgen INC. | $5,946.32 | 2024-2025 | Uplizna |
| Ucb, INC. | $4,474.03 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $3,411.78 | 2022-2025 | |
| Tg Therapeutics, INC. | $2,154.35 | 2023-2025 | |
| Genentech, INC. | $1,760.52 | 2019-2025 | Ocrevus |
| E.R. Squibb & Sons, L.L.C. | $1,280.00 | 2024 | |
| Biogen, INC. | $699.19 | 2021-2025 | Tysabri, Vumerity |
| Vanda Pharmaceuticals INC. | $209.31 | 2024-2025 | Ponvory |
| Celgene Corporation | $144.37 | 2023-2025 | Zeposia |
| Genzyme Corporation | $143.24 | 2024-2025 | |
| Horizon Therapeutics Plc | $120.11 | 2022 | |
| Therapeuticsmd, INC. | $17.53 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.